Slavik M
Cancer Treat Rep. 1979 Jun;63(6):1041-4.
6-Azauridine triacetate (6-AzUrd-TA) administration causes changes in amino acid metabolism both in experimental animals and in man. This effect is dose-related. Amino acid changes caused by 6-AzUrd-TA resemble those in inborn homocystinuria, beta-alaninemia, and hyperhistidinemia. Inhibition of certain enzymes using pyridoxal phosphate as a coenzyme appears to be the common denominator for these changes. There is supportive evidence suggesting that homocystinemia and thrombotic episodes, both caused by 6-AzUrd-TA, are related. These results also reveal that anticancer drugs other than amino acid analogs and amino acid-depleting enzymes may cause significant changes in amino acid metabolism. Their detection and correlation with the therapeutic or adverse effects can be used as an alternative method for studying the relevance of amino acid changes to the treatment of cancer.
给予三乙酸6-氮杂尿苷（6-AzUrd-TA）会使实验动物和人体的氨基酸代谢发生变化。这种效应与剂量相关。6-AzUrd-TA引起的氨基酸变化类似于先天性高胱氨酸尿症、β-丙氨酸血症和高组氨酸血症中的变化。使用磷酸吡哆醛作为辅酶对某些酶的抑制似乎是这些变化的共同特征。有支持性证据表明，由6-AzUrd-TA引起的高胱氨酸血症和血栓形成事件是相关的。这些结果还表明，除氨基酸类似物和消耗氨基酸的酶之外的抗癌药物可能会导致氨基酸代谢发生显著变化。对它们的检测以及与治疗效果或不良反应的关联可作为研究氨基酸变化与癌症治疗相关性的替代方法。
